Skip to main content
OpenTrials
Completed

NCT Number: NCT02642822

The Epidemiologic Study of Human Cytomegalovirus(CMV) in Female Students of Xiamen University

In this study, 100 female students aged 18 to 30 years old in Xiamen University will be enrolled. On the first visit, blood, saliva and urine samples of all participants will be collected. Then saliva and urine samples will be collected at two-week interval until 6 months. Serum samples will be tested the PP150-IgG titer. Saliva and urine samples will be used to test CMV DNA by PCR. The primary purpose of this study is to identify the relationship between baseline PP150-IgG titer and CMV infection.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–30 year

Sex eligibility

Female

Study type

Observational

Primary location

School of public health of Xiamen University

Xiamen, Fujian, 361000, China

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • 18-30 years old
  • female students of Xiamen University

Exclusion criteria

  • students who have the serious diseases

Treatment and study plan

Primary outcomes

  1. rate of active CMV infection in different PP150-IgG titer

    Time frame: 1 year

Sponsors and collaborators

Lead sponsor

Jun Zhang

Other

Registry information

Official study title

The Epidemiologic Study of Human Cytomegalovirus (CMV)in Female Students of Xiamen University

Important dates

Study start
2014
Primary completion
2016
Study completion
2016
First posted
Dec 30, 2015
Registry last updated
Jul 14, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.